In many therapeutic areas, immunotherapy using CD19-targeted CAR-T therapy is being introduced as a new and promising treatment for systemic lupus erythematosus (SLE), regulatory rheumatoid factor (regRF) bring into being lymphocytes also use therapeutic targets in rheumatoid arthritis (8–10). This evidence concerns the gene CD19 and systemic lupus erythematosus.